Pharmaceutical combination for the treatment of cancer
A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.
1. A pharmaceutical combination for the treatment of cancer comprising:
(i) a Compound (A) which comprises a polyunsaturated fatty acid of formula COOH-CHOH-(CH 2 ) 6 -(CH=CH-CH 2 ) 2 -(CH 2 ) 3 -CH 3 (ABTL0812), a pharmaceutically acceptable salt thereof, or a combination thereof
and
(ii) a Compound (B) which comprises at least one chemotherapeutic agent compound selected from the group consisting of: Docetaxel; Paclitaxel; Nab-paclitaxel; Carboplatin; Cisplatin; Oxaliplatin;
and Retinoic acid;
wherein the cancer is selected from the group consisting of lung cancer; squamous cell cancer;
adenocarcinoma; endometrial cancer; pancreatic cancer; glioblastoma; breast cancer; head and neck cancer; neuroblastoma; and cholangiocarcinoma.
2. The pharmaceutical combination of claim 1 , wherein Compound (A) comprises a sodium salt of COOH-CHOH-(CH 2 ) 6 -(CH=CH-CH 2 ) 2 -(CH 2 ) 3 -CH 3 (ABTL0812).
3. The pharmaceutical combination of claim 1 , wherein the pharmaceutical combination is a single composition comprising both Compound (A) and Compound (B).
4. The pharmaceutical combination of claim 1 , wherein Compound (B) comprises: Paclitaxel and Carboplatin; Paclitaxel and Gemcitabine; Nab-Paclitaxel and Gemcitabine;
Cisplatin and Gemcitabine; or Cisplatin and Pemetrexed.
5. A method to treat a cancer in a subject in need thereof comprising administering a pharmaceutically effective amount of a pharmaceutical combination of claim 1 to the subject wherein the cancer is selected from the group consisting of lung cancer;
squamous cell cancer; adenocarcinoma; endometrial cancer; pancreatic cancer; glioblastoma; breast cancer; head and neck cancer; neuroblastoma; and cholangiocarcinoma.
6. The method of claim 5 , wherein
Compound (B) comprises docetaxel and the cancer is lung cancer;
Compound (B) comprises paclitaxel and the cancer is lung cancer;
Compound (B) comprises carboplatin and the cancer is endometrial cancer;
Compound (B) comprises paclitaxel and the cancer is breast cancer;
Compound (B) comprises paclitaxel and carboplatin and the cancer is squamous cell cancer;
Compound (B) comprises paclitaxel and carboplatin and the cancer is non-small cell lung adenocarcinoma;
Compound (B) comprises paclitaxel and the cancer is endometrial cancer;
Compound (B) comprises paclitaxel and carboplatin and the cancer is endometrial cancer;
Compound (B) comprises paclitaxel and gemcitabine and the cancer is pancreatic cancer;
Compound (B) comprises cisplatin and gemcitabine and the cancer is neuroblastoma;
Compound (B) comprises pemetrexed and cisplatin and the cancer is non-small cell lung adenocarcinoma;
or
Compound (B) comprises cisplatin and gemcitabine and the cancer is cholangiocarcinoma.